Editorial

Helicobacter pylori Treatment

Authors: Murali Krishna, MD, Judy Lalmuanpuii, MD

Abstract

Helicobacter pylori is a Gram negative bacterium that was isolated in 1983 and has since been shown to be associated with peptic ulcer disease as well as gastric adenocarcinoma and gastric lymphoma. It has a worldwide prevalence. The rate of infection varies among different ethnic groups and socioeconomic strata. The overall prevalence in the United States is thought to be 10%.1

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Peterson WL, Graham DY. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Philadelphia, W.B. Saunders, 7th ed, 2002.
 
2.Howden CW, Hunt RH. Guidelines for the Management of Helicobacter pylori Infection Am J Gastro1998;93:2330–2338.
 
3.Datta S, Chattopadhyay S, Patra R, et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther 2005;22:51–57.
 
4.De la Torre PM, Torrado G, Torrado S. Poly (acrylic acid) chitosan interpolymer complexes for stomach controlled antibiotic delivery. J Biomed Mater Res B Appl Biomater 2005;72:191–197.
 
5.Nilius M, Malfertheiner P. Helicobacter pylori enzymes Aliment Pharmacol Ther 1996;10 (Suppl 1):65–71.
 
6.Huynh HQ, Couper RT, Tran CD, et al. N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Dig Dis Sci 2004;49:1853–1861.
 
7.Logan RPH, Bardhan KD, Celestin LR. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-center trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther 1995;9:417–424.